Published in Cell Death Dis on June 30, 2016
Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell Death Dis (2016) 0.75
A regulated PNUTS mRNA to lncRNA splice switch mediates EMT and tumour progression. Nat Cell Biol (2017) 0.75
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol (2008) 24.27
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 16.92
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
Cancer statistics in China, 2015. CA Cancer J Clin (2016) 12.92
Caspases: the executioners of apoptosis. Biochem J (1997) 11.99
Characterization of microRNA expression profiles in normal human tissues. BMC Genomics (2007) 8.01
Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem (1998) 6.84
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst (2005) 4.48
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther (2002) 3.55
MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov (2013) 3.33
Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2013) 3.29
MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther (2008) 3.06
Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther (2008) 2.85
VEGF targets the tumour cell. Nat Rev Cancer (2013) 2.71
Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol (2013) 2.69
Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res (2009) 2.65
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res (2009) 2.59
microRNA-205 regulates HER3 in human breast cancer. Cancer Res (2009) 2.53
Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer (2011) 2.49
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res (2013) 2.30
The shaping and functional consequences of the microRNA landscape in breast cancer. Nature (2013) 2.22
A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A (2002) 2.16
Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem (2003) 2.06
Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem (2011) 1.73
miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem (2011) 1.63
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov (2013) 1.54
Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol (2004) 1.49
Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol (2012) 1.48
MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth. Cancer Lett (2013) 1.44
Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res (2013) 1.40
Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res (2013) 1.23
Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Oncogene (2013) 1.19
Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle (2010) 1.18
Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol (2004) 1.16
The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol (2010) 1.15
Biological and prognostic associations of miR-205 and let-7b in breast cancer revealed by in situ hybridization analysis of micro-RNA expression in arrays of archival tumour tissue. J Pathol (2012) 1.12
Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene (2010) 1.08
Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA. Breast Cancer Res (2015) 1.08
MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. J Clin Invest (2014) 1.07
miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun (2014) 1.06
Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors. Pharm Res (2006) 1.03
Caspase-mediated programmed cell death pathways as potential therapeutic targets in cancer. Cell Prolif (2012) 1.00
MiR-497 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting VEGFA and AEG-1. Oncotarget (2015) 0.99
MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma. Urol Oncol (2015) 0.96
Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget (2010) 0.96
miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer. Breast Cancer Res Treat (2015) 0.96
miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. Biochem Pharmacol (2013) 0.95
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood (2014) 0.94
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget (2015) 0.93
The miR-106b~25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300. Cell Death Differ (2013) 0.93
The Role of MicroRNAs in the Chemoresistance of Breast Cancer. Drug Dev Res (2015) 0.83
MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. Cell Signal (2015) 0.82
Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins. Cancer Chemother Pharmacol (2013) 0.81
miR-106b~25 cluster regulates multidrug resistance in an ABC transporter-independent manner via downregulation of EP300. Oncol Rep (2015) 0.81
Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms. PLoS One (2012) 0.80
Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells. Cell Death Dis (2015) 0.79
Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells. Biochem Pharmacol (2012) 0.79
Modulatory role of miR-205 in angiogenesis and progression of thyroid cancer. J Mol Endocrinol (2015) 0.78
miR-205 suppresses the proliferative and migratory capacity of human osteosarcoma Mg-63 cells by targeting VEGFA. Onco Targets Ther (2015) 0.76